Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
LISINOPRIL
Cardiovascular · Cardiovascular · Level 3
|
RAMIPRIL
Cardiovascular · Cardiovascular · Level 3
|
|---|---|---|
| Mechanism of action | Competitive inhibition of angiotensin converting enzyme leads to decreased angiotensin II production and its effects. |
Competitive inhibition of angiotensin converting enzyme leads to decreased angiotensin II production and its effects. |
| Physiological effects | CVS Renal Metabolic |
CVS Renal Metabolic |
| Absorption | PO. absorbed variably. BA: 30% |
PO. 50–60% is absorbed. BA: 30% |
| Protein binding | 25% |
75% |
| Volume of distribution | 1.7 L/kg |
0.1 L/kg |
| Metabolism | not metabolised |
Hepatic to the active form, ramiprilat |
| Excretion | urine unchanged |
Urine (60%) and feces (40%) as parent drug & metab |
| Half-life | 12 hours |
triphasic elimination profile of the active metabolite ramiprilat with T1/2 1-2 hrs, 13-17hrs and >50hrs. |
| Adverse Effects Toxicity | A dry cough may occur especially in patients with pre-existing lung disease. |
A dry cough may occur especially in patients with pre-existing lung disease. |
| Class Group | ACE inhibitor |
ACE inhibitor |
| Indications Uses | used for management of hypertension, LV dysfunction post myocardial infarction and in the setting of heart failure. |
used for management of hypertension, LV |
| Introduction | Active drug that is not metabolised and is excreted directly into urine. It is a competitive ACE inhibitor |
prodrug requiring hepatic activation to ramiprilat. |
| Legacy Cicm Level | Level 3 |
Level 3 |
| Onset Peak Duration | highly potent |
potent |
| Presentation | oral formulation presented as white tablets in dosage ranging from 5mg |
oral formulation presented as tablets or capsules in dosage ranging from |
| Route And Dose | PO: doses commenced at 6.25mg TDS and uptitrated |
PO: doses commenced at 2.5 mg Daily and uptitrated |